Table 1.
Burden analysis in full cohort (n=8,165 cases and n=70,363 controls) | Burden analysis in early onset (<50) cases only (n=818 cases and n=7,427 controls) | ||||||
---|---|---|---|---|---|---|---|
Cohort | Variants included in analysis | P-value | Pfdr | N of varaints | P-value | Pfdr | N of vairants |
AMP_PD | All rare | 1.42E-05 | 2.98E-04 | 523 | 3.48E-05 | 7.31E-04 | 471 |
AMP_PD | Nonsynonymous | 0.241 | 0.633 | 26 | 0.273 | 0.956 | 23 |
AMP_PD | CADD | 0.248 | 0.579 | 9 | 0.298 | 0.894 | 9 |
Columbia | All rare | 0.030 | 0.126 | 66 | 0.574 | 0.927 | 40 |
Columbia | Nonsynonymous | 0.012 | 0.084 | 25 | 0.044 | 0.231 | 15 |
Columbia | CADD | 0.641 | 0.841 | 15 | 0.375 | 0.984 | 7 |
McGill | All rare | 0.009 | 0.095 | 62 | 0.027 | 0.189 | 31 |
McGill | Nonsynonymous | 0.693 | 0.809 | 24 | 0.573 | 1.000 | 13 |
McGill | CADD | 0.665 | 0.821 | 19 | 0.592 | 0.888 | 10 |
Pavlov and Human brain | All rare | 0.448 | 0.941 | 75 | 0.807 | 0.847 | 38 |
Pavlov and Human brain | Nonsynonymous | 0.605 | 0.847 | 35 | 0.631 | 0.779 | 17 |
Pavlov and Human brain | CADD | 0.578 | 0.867 | 37 | 0.74 | 0.863 | 17 |
Sheba | All rare | 0.720 | 0.796 | 23 | 0.608 | 0.851 | 16 |
Sheba | Nonsynonymous | 0.733 | 0.770 | 8 | 0.464 | 0.974 | 5 |
Sheba | CADD | 0.463 | 0.884 | 6 | 0.405 | 0.945 | 6 |
UKBB | All rare | 0.530 | 0.856 | 440 | 0.827 | 0.825 | 180 |
UKBB | Nonsynonymous | 0.779 | 0.779 | 163 | 0.464 | 0.809 | 24 |
UKBB | CADD | 0.497 | 0.870 | 67 | 0.673 | 0.831 | 78 |
Meta-analysis | All rare | 0.025 | 0.131 | 2.80E-03 | 0.029 | ||
Meta-analysis | Nonsynonymous | 0.090 | 0.315 | 0.217 | 0.951 | ||
Meta-analysis | CADD | 0.120 | 0.361 | 0.485 | 0.953 |
UKBB – UK biobank, AMP-PD – Accelerating Medicines Partnership – Parkinson Disease; Combined Annotation Dependent Depletion (CADD) score >20, Pfdr- p-value with false discovery rate adjustment.